Transaction #1252 · Form 4 · 0001193125-25-242700
Xenon Pharmaceuticals Inc. · Stock award · Share Option (Right to Buy)
Xenon Pharmaceuticals Inc. · Transacted October 15, 2025 · Filed October 17, 2025
What does this filing report?
An SEC Form 4 filing for Xenon Pharmaceuticals Inc. records a stock award involving Share Option (Right to Buy) on October 15, 2025. The reported quantity was 225,000. The filing date is October 17, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Xenon Pharmaceuticals Inc.
- Company CIK
- 0001582313
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 225,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 225,000
- Ownership description
- Not reported
- SEC acceptance time
- Oct 17, 2025, 6:43 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Kelly Thomas Patrick ↗
Chief Financial Officer
CIK 0001410514
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Shares
- Underlying quantity
- 225,000
- Conversion / exercise price
- 41.9
- Exercise date
- Not reported
- Expiration date
- October 14, 2035
Filing footnotes & remarks
- F1
- Vesting 25% on October 15, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
- F2
- Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on October 15, 2026.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.